Advertisement
Advertisement

TheBody.com/TheBodyPRO.com covers The 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)

CROI 2012: Hep C Drug Incivek Improves HCV Cure Rate in People With HIV

March 26, 2012

Results from a small study of 62 co-infected people treated with Incivek showed that 74% had undetectable viral loads at 12 weeks after stopping their hepatitis C treatment, compared to 45% on pegylated interferon + ribavirin alone. About one-quarter were not on HIV treatment (13) while most (47) were taking Atripla or boosted Reyataz (atazanavir) + Truvada (Viread/tenofovir + Emtriva/emtricitabine).

Incivek + pegylated interferon + ribavirin was given for the first 12 weeks, and then interferon + ribavirin only for the next 36 weeks. The average age of the participants was 45, and only 15% were women. Most people had HCV viral loads above 800,000, while 10% had advanced liver fibrosis. Nearly 68% had HCV genotype 1a while the others had 1b, both of which are more difficult to treat types.

The following chart describes 12-week post-treatment undetectable HCV viral loads (T/PR = Incivek + pegylated interferon + ribavirin):


  No HIV meds Atripla Reyataz Total
Undet. HCV T/PR PR T/PR PR T/PR PR T/PR PR
4 wks 71% 0% 75% 12% 60% 0% 68% 5%
12 wks 86% 33% 88% 25% 73% 38% 82% 32%
24 wks 86% 0% 75% 50% 67% 75% 74% 55%
12 wks post 71% 33% 69% 50% 80% 50% 74% 45%


The following details should be noted about this study:

  • 25 people had stopped HCV treatment by week 48.
  • Those who took Sustiva had their Incivek dose increased to 1,125mg from 750mg due to known interaction between the two drugs.
  • Despite undetectable HCV viral loads at week 48, three people had their HCV levels return.
  • CD4 counts tended to decrease in everyone, a common response to HCV treatment in co-infection. However, the CD4% did not change.
  • No one experienced detectable HIV viral load.
  • High rates of side effects were seen in the Incivek group, including: headache (37%), nausea (34%), rash (34%), itching (39%), fever (21%), anemia (18%), and depression (21%).

Larger studies will be conducted. These will include people new to HCV treatment, people who rebounded after HCV treatment, partial responders, and non-responders.




This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement